Irbesartan

As a provider accredited by the Accreditation Council for Continuing Medical Education ACCME ; , it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or provider has with the manufacturer s ; of any commercial product s ; discussed in an educational presentation. The presenting faculty reported the following: Drs. Roberts and Rodriguez have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to this article. No faculty member has indicated that the presentation will include information on off-label products, for example, irbesartan diabetic nephropathy. 13. Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, Shen X, Wu M, Zhou G, Doebber T, Berger J, Moller DE and Zhang BB. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 51: 2412-2419, 2002. Jugdutt BI and Balghith M. Enhanced regional AT 2 ; -receptor and PKC epsilon ; expression during cardioprotection induced by AT 1 ; -receptor blockade after reperfused myocardial infarction. Journal of the Renin-Angiotensin-Aldosterone System 2: 134-140, 2001. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma PPAR gamma ; . Journal of Biological Chemistry 270: 12953-12956, 1995. Li DM, Saldeen TM, Romeo FM and Mehta JLM. Oxidized LDL Upregulates Angiotensin II Type 1 Receptor Expression in Cultured Human Coronary Artery Endothelial Cells: The Potential Role of Transcription Factor NF-[kappa]B. Circulation 102: 1970-1976, 2000. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M and Chambon P. The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995. Marrero MB, Fulton D, Stepp D and Stern DM. Angiotensin II-Induced Insulin Resistance and Protein Tyrosine Phosphatases. Arteriosclerosis, Thrombosis & Vascular Biology 24: 2009-2013, 2004. Mehta JL HBCJLD. Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation. Arterioscler Thromb Vasc Biol 2003. 20. Miyoshi H, Takayama Y, Kitashiro S, Izuoka T, Saito D, Imuro Y, Mimura J, Yamamoto S, Tokioka M and Iwasaka T. Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs. Japanese Journal of Pharmacology 89: 120-125, 2002. Molavi B. CHLDMJL. Preservation of left ventricular function following ischemia-reperfusion by PPAR- ligands. Circulation 106: 934, 2003. Moudgil R, Xu Y, Menon V and Jugdutt BI. Effect of chronic AT 1 ; receptor antagonism on post ischemic functional recovery and AT 1 ; AT receptor proteins in isolated working rat hearts. Journal of Cardiovascular Pharmacology & Therapeutics 6: 183-188, 2001. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE and Dzau VJ. The angiotensin II type 2 AT2 ; receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proceedings of the National Academy of Sciences of the United States of America 92: 10663-10667, 1995. Preckel B, Schlack W, Gonzalez M, Obal D, Barthel H and Thamer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia reperfusion injury in the dog heart. Basic Research in Cardiology 95: 404-412, 2000. Starting ACE-I AT2RA therapy Caution in patients with PVD may have renovascular disease ; Caution in patients with creatinine 150umol l Use maximal tolerated doses of evidencebased drugs: eg. lisinopril aim for 20-40mg od ; , ramipril aim for 10mg od ; , irbesartan aim for 300mg od ; , losartan aim for 100mg od ; In all patients, measure serum creatinine and electrolytes 1 week after: - initiating therapy - dosage increase A non-progressive rise of serum creatinine of 30% is usually acceptable and avodart.
Jurgen Janke, Franz-Volhard-Klinik, Charite Campus Buch; HELIOS Klinikum Berlin, Berlin, Germany; Michael Schupp, Cntr for Cardiovascular Rsch, Charite Campus Mitte, Berlin, ` Germany; Stefan Engeli, Kerstin Gorzelniak, Franz-Volhard-Klinik, Charite Campus Buch; HELIOS Klinikum Berlin, Berlin, Germany; Lilian Said, Frederik H Nystrom, Dept of Medicine and Care, Faculty of Health Sciences, Linkoping Univ, Linkoping, Sweden; Friedrich C Luft, Franz-Volhard-Klinik, Charite Campus Buch; HELIOS Klinikum Berlin, Berlin, Germany; Arya M Sharma; Dept of Medicine, McMaster Univ, Hamilton, Canada Unexpected metabolic effects of RAS-blockade reduced the risk to develop type 2 diabetes mellitus by 22% in large randomized controlled trials. The underlying mechanism of the insulin-sensitizing anti-diabetic effect of ARBs is not known as yet. Activation of PPAR by telmisartan in mouse clonal preadipocytes has recently been described, leading to increased adipogenesis. As newly differentiated small adipocytes are more insulin sensitive than old and large adipocytes, the adipogenic potential of ARBs is clearly of interest. To elucidate the underlying mechanism of the anti-diabetic effect of ARBs in humans, we investigated the activation of PPAR by different ARBs in human preadipocytes and adipocytes. In vitro studies revealed PPAR -like effects for telmisartan and irbesartan, less strong effects for losartan and no PPAR -like effects of eprosartan. These effects included the induction of adipogenesis and the activation of PPAR -target genes adiponectin and lipoprotein lipase ; on mRNA and protein levels. Furthermore, transfection assays of isolated human adipocytes demonstrated activation of the luciferase reporter gene by all sartans, the induced activity of PPAR was approximal 2-fold with pioglitazone and 1.5-fold with each sartan. The data suggest that ARBs have effects on adipogenesis and PPAR -target gene expression in human adipose cells that are independent of the blockade of the adipocyte AT1-receptor, but linked to improved insulin sensitivity.
ESTROGENS CONJ. OR ESTD. ; ESTROPIPATE * ETH. ESTRADIOL; NORETH. ACE. ETODOLAC * FELODIPINE FENOFIBRATE FLURBIPROFEN * FLUVASTATIN SODIUM FLUVASTATIN SODIUM FOSINOPRIL SODIUM FUROSEMIDE * GEMFIBROZIL * GLIMEPIRIDE GLIPIZIDE * GLIPIZIDE GLYBURIDE * GLYBURIDE MICRONIZED ; * GLYBURIDE METFORMIN GUANFACINE HCL * HCTZ HYDRALAZINE RESERPINE * HCTZ TRIAMTERENE * HYDRALAZINE HCL * HYDROCHLOROTHIAZIDE * IBUPROFEN * INDAPAMIDE * INDOMETHACIN * IRBESARTAN HCTZ ISONIAZID * ISOSORBIDE DINITRATE * ISRADIPINE LABETALOL HYDROCHLORIDE * LEVOTHYROXINE SODIUM * LIOTHYRONINE SODIUM LIOTRIX LISINOPRIL * LISINOPRIL HCTZ * LOSARTAN POTASSIUM LOVASTATIN * MEDROXYPROGEST. ACETATE * MELOXICAM METAPROTERENOL SULFATE * METFORMIN METFORMIN HYDROCHLORIDE * METHAZOLAMIDE and dutasteride. Candesartan cilexetil atacand astra ; 4 mg, 8 mg and 16 mg tablets approved indication: hypertension amh section 5 two at 1 receptor antagonists losartan and irbesartan ; are already available in australia. Three companysponsored studies1, 2, 3 which show that angiotensin II blockers can slow the progression of nephropathy in patients with type 2 diabetes have been published in the New England Journal of 1 Medicine. Two studies, one using losartan 2 and one irbesartan , assess benefits in patients with type 2 diabetes and nephropathy. The third study3, investigates irbesartan in patients with type 2 diabetes and microalbuminuria. Diabetic nephropathy is the leading cause of end-stage renal disease. Both the prevalence and the incidence of end stage renal disease have approximately doubled in the last ten years, with about 40% of cases relating to diabetes. Although ACE inhibitors have been shown to slow the progress of nephropathy most studies have been completed in patients with type 1 rather 4 than type 2 diabetes. Losartan and diabetic nephropathy1 1513 patients with type 2 diabetes and nephropathy were randomised to losartan 50mg daily or placebo. The dose of losartan could be increased to 100mg daily if the patient's blood pressure was above the study target of 140 90mmHg. All subjects were allowed to use conventional antihypertensives except ACE inhibitors ; as necessary. Patients were followed for a mean of 3.4 years. The primary outcome was a composite of a doubling of the baseline serum creatinine concentration, endstage renal disease or death. Secondary end points included a composite of morbidity and mortality from cardiovascular causes, proteinurea and the rate of progression of renal disease. 327 patients in the losartan group reached the primary endpoint compared to 359 in the placebo group 16% risk reduction, p 0.02 ; . Losartan reduced the incidence of a doubling in serum creatinine concentration 25% RR, p 0.006 ; and end stage renal disease 38% RR, p 0.002 ; but had no effect on the rate of death. The incidence of secondary endpoints was similar between the two groups. However, the rate of hospitalisation from heart failure was significantly lower in the losartan group 32% RR, p 0.005 ; . Patients in the losartan group also had a significant decline in the level of proteinurea 35% reduction, p 0.001 compared to placebo ; . The authors comment that the use of losartan in this group of patients led to significant improvements in renal outcomes beyond that expected from blood pressure control. Irb3sartan vs. amlodipine and diabetic 2 nephropathy 1715 hypertensive patients with nephropathy due to type 2 diabetes were randomised to irbesartan 300mg daily, amlodipine 10mg daily, or placebo. The target blood pressure was 135 85mmHg or less in all groups. Antihypertensive agents other than ACE inhibitors, angiotensinreceptor blockers, and calcium channel blockers were used as needed in each group. The primary composite end point was a doubling of the base-line serum creatinine concentration, the development of end-stage renal disease, or death from any cause. A secondary, cardiovascular end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, heart failure resulting in hospitalisation, a permanent neurologic deficit caused by a cerebrovascular event, or a lower limb amputation. Patients were reviewed every 3 months, and followed up for a mean duration of 2.6 years. Patients in the irbesartan group had a 20% lower incidence of the primary composite end point than the placebo group and a 23% lower incidence compared to the amlodipine group p 0.006 ; . The risk of a doubling of the serum creatinine concentration was 33% lower in the irbesartan group than in the placebo group p 0.003 ; and 37% lower than in the amlodipine group p 0.001 ; . Treatment with irbesartan was associated with a 23% lower relative risk of end-stage renal disease than in both other groups p 0.07 for both ; . These differences were not explained by differences in the blood pressures achieved. The serum creatinine concentration increased 24% more slowly in the irbesartan group than in the placebo group p 0.008 ; and 21% more slowly than in the amlodipine group p 0.02 ; . There were no significant differences in the rates of death from any cause or in the cardiovascular composite end point. Irbesartab and microalbuminuria3 590 hypertensive patients with type 2 diabetes and microalbuminuria were enrolled and randomised to irbesartan 150mg daily, irbesartan 300mg daily, or placebo. Patients were followed up for 2 years. The primary outcome was the time to the onset of diabetic nephropathy assessed by clinical microalbuminuria ; . Ten 5.2% ; patients in the 300mg-group and 19 9.7% ; patients in the 150mggroup developed diabetic nephropathy, compared with 30 14.8% ; patients in the placebo group hazard ratios 0.30 [95% CI 0.14-0.61, p 0.001] and 0.61 [0.34-1.08, p 0.08] for the 2 irbesartan groups respectively ; . The average and abacavir. Session Chair: Professor Nancy Pedersen 09.0009.30 Industry Perspectives of Population Genomics Dr Alun McCarthy, GSK 09.3010.00 Translational Research Professor John Bell, University of Oxford 10.0010.30 Coffee and poster viewing 10.3012.30 Forum and debate Expectations and goals for industry and healthcare Chairs: Professor David Porteous and Professor Bartha Knoppers 12.3013.45 Lunch and poster viewing Session Chair: Professor Luisa Bernardinelli 13.4514.15 Lecture on resources relevant to population genomics Professor G Van Ommen, University of Leiden 14.1514.45 Lecture on statistical analysis in population genomics Professor L Cardon, University of Oxford 14.4515.15 Tea and poster viewing 15.1517.15 Forum and debate Future needs for resources and tools for statistical analysis Chairs: Professor Dorret Boomsma and Professor Thomas Meitinger Session Chair: Professor Bartha Knoppers, P3G 17.1518.00 Strategic lecture on the social impact of human population genomics Professor H Galjaard, Erasmus University 19.30 Conference dinner. Each film-coated tablet contains either 150 mg irbesartan and 12.5 mg hydrochlorothiazide or 300mg irbesartan with 12.5 mg hydrochlorothiazide. For excipients, see 6.1. 3. PHARMACEUTICAL FORM and ziagen.

The medication should be tried at the prescribed dose for the full six weeks before evaluating its effectiveness.
Fluox prozac fluoxetine irovel avapro irbesartan mesacol asacol mesalamine pentasa norpace disopyramide taxim-o cefixime suprax anafranil clomipramine glucophage metomin prozac fluoxetine lioresal baclofen premarin conjugated estrogen atacand candesartan atorlip atorvastatin lipitor cipramil celexa citalopram condyline podophyllotoxin dapsone dds distinon pyridostigmine mestinon mestinon timespan doxin doxepina apin sinequan imigran imitrex imuzat azathioprine imuran muse alprostadil pellets nail batrafen penlac rosuvas crestor rosuvastatin simvofix simvastatin zocor claratyne claritan retinova tretinoin serevent salmeterol carisoma soma carisoprodol dostinex cabergoline zestril prinivil lisinopril ocuvir acyclovir zovirax neurontin oxa forte paracetamol codeine paxil cr phenergan progra propecia propinolox proscar proxyvon prozac revez naltrexone risperdal risperin rivotril clonazepam roaccutan accutane sildenafil somit ambien strattera tamiflu taxagon elvetium tegretol tranquinal trapax trapax lorazepam tryptanol amitriptyline uprima valium valtrex viagra vigicer modafinil viranet valacyclovir wellbutrin xanax xenical zithromax zolax zolfresh zolpidem zoloft zyprexa olanzapine zyrtec rontag a b c full alphabetical index drugs and salbutamol and irbesartan. What is the difference between these pills 20th june 2006. Calcium is a divalent metal essential for the maintenance of the nervous, muscular, and skeletal systems as well as for cell membrane and capillary permeability and alfacalcidol. Gift box with plates, bowls and cutlery for two table sets: TWS two white porcelain plates 25 H.2, 4 ; by Antonia Astori. TWS KINGYO two dessert plates 20 H.2 ; , two small plates 9 H.1, 5 TWS COLOURS two pelargonium red bowls in porcelain 6, 2 H.4, 7 ; , two purple bowls in porcelain 13 H.6, 5 ; . All the decors are by Vittorio Locatelli. Sticks MIAMIAM in stainless steel by Philippe Starck.
Papademetriou V. Selection of Antihypertensive Therapy for Patients With Hypertensive Renal Disease. JAMA 2001; 285: 2774-2776. Parving H-H, Lehnert H, Brochner-Mortenson J, Gomis R, Andersen S, Arner P, for the Irvesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. NEJM 2001; 345: 870-878. Pescatello, LS. Exercising for Health: The Merits of Lifestyle Physical Activity. WJM 2001; 174: 114-118. Pickering TG. Lessons from the Trials of Hypertension Prevention, Phase II editorial ; . Arch Intern Med 1997; 157: 596-597. Pickering TG. Obesity and Hypertension: What Should We Do? editorial ; . Ann Intern Med 2001; 134: 7274. Reardon LC, Macpherson DS. Hyperkalemia in Outpatients Using Angiotensin-Converting Enzyme Inhibitors: How Much Should We Worry? Arch Intern Med 1998; 158: 26-32. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin P-H, for the DASH-Sodium Collaborative Research Group. NEJM 2001; 344: 3-10. Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension AASK ; : New Findings. J Clin Hypertens Greenwich ; 2001; 3: 244-251. SlataperR, Vicknair N, Sadler R, Bakris GL. Comparative Effects of Different Antihypertensive Treatments on Progression of Diabetic Renal Disease. Arch Intern Med 1993; 153: 973-980. Sowers JR, Bakris GL. Antihypertensive Therapy and the Risk of Type 2 Diabetes Mellitus editorial ; . NEJM 2000; 342: 969-970. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, Mattfeldt-Beman M, Oberman A, Sugars C, Dalcin AT, Whelton PK, for the TOHP Collaborative Reasearch Group. Arch Intern Med 1993; 153: 849-858. Stevens VJ, Obarzanek E, Cook NR, Lee I-M, Appel LJ, Smith D, Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, Singh B, Cohen J, for the Trials of Hypertension Prevention Research Group. Ann Intern Med 2001; 134: 72-74. The Joint National Committeeon Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Eduction Program Coordinating Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446. Toto R. Angiotensin II Subtype 1 Receptor Blockers and Renal Function. Arch Intern Med 2001; 161: 1492-1499.
Submission to the Minister of Health by the Dr. Rath Health Foundation concerning the proposed amendment of the Regulations to the Medicines and Related Substances Act. Irbesartan - Madrid et al., 2002. This medication causes little nausea and avodart.
Ew approaches to treating chronic diseases are being prioritised by clinical researchers and, as a result, more emphasis is being placed on demonstrating clear long-term benefits with regard to mortality survival ; and morbidity endpoints. Such studies tend to be global in nature, involve thousands of patients, and require long-term treatment and follow-up. Mortality and morbidity studies represent one of the major investments and risks ; that a company involved in developing an investigational medicinal product can take. Therefore, it is important to find ways to improve the processing and management of clinical data in studies using mortality and morbidity as an endpoint although improving these processes will also benefit any endpoint-driven study. In particular, this article explores the use of web-based systems and software to control development times and costs.1 Such technology includes interactive voice recognition systems for patient randomisation and clinical trials supplies, electronic case report forms CRFs ; and patient diary cards for faster collection and processing of clinical data, and electronic dossier submissions of marketing authorisation applications. For this article, we reviewed how an event reported by the patient at a site is identified, processed, and confirmed as an endpoint by an independent panel of experts. From the outset, we believed web-based technology would provide a necessary `platform' to introduce more efficient information flow from the source the patient ; to endpoint confirmation the independent panel of experts ; . However, before describing how webbased technology has improved information flow between everyone involved in the clinical study, it is important to consider endpoints themselves, as these are central to confirming efficacy and or safety in this type of study see Box210.
Pitt article information received: received: october 24, 2001 accepted: february 8, 2002 number of print pages : 5 number of figures : 0 , number of tables : 1 , number of references : 21 free abstract article references ; article pdf 62 kb ; journal home journal content guidelines. Diet pills offered here, however, are either pharmaceutical grade appetite suppressants or scientifically formulated to work with your body to make you feel less hungry or block carbs while giving you more energy at the same time. During the recent years, it has become apparent that inheritable ion channel abnormalities play an important role in the pathogenesis of several cardiac tachyarrhythmias, such as the long QT syndrome 278 ; . In addition, Lerman et al 279 ; showed that a mutation in the inhibitory branch of the cAMP signal transduction pathway may result in idiopathic right ventricular outflow tract tachycardia that is unresponsive to adenosine. Wising 165 ; previously provided evidence that IST is a heritable disorder, and knockout of the IKAch, Ado protein in mice causes a state that closely resembles IST 280, 281 ; . Hence, it is tempting to speculate that a specific gene mutation controlling the function of the IKAch, Ado protein is the basic abnormality behind IST. Nevertheless, the underlying cause s ; of IST may be heterogeneous 173 ; . The present data provide new insight into the possible mechanism s ; of IST. First, the resistance of IST to the antiarrhythmic action of adenosine argues against triggered 96, 201 ; activity as the principal mechanism of IST. Second, the higher than normal IHR supports the previous notion that the mechanism s ; of IST involve s ; a primary abnormality of the sinus node rather than abnormal autonomic modulation 29 ; . Given the accentuation of the effect of adenosine on the sinus node by beta-adrenergic stimulation 257 ; , the impaired response to adenosine makes excessive sympathetic input unlikely as a primary mechanism of IST. Third, at the cellular level, an impaired negative chronotropic effect to adenosine suggests that either the indirect anti--adrenergic ; or preferably the direct Gi, o -protein-mediated signal transduction pathway is malfunctioning in patients with IST. Accordingly, we postulate that IST may result from a deficient function of the IKAch, Ado channel. Because the A1-adenosine receptors and the muscarinic cholinergic system share the same receptor-effector pathway 277 ; , this could explain not only the impaired negative chronotropic response to adenosine but also the blunted response to vagal input in the patients with IST 1, 171 ; . This interpretation is supported by several experimental findings. Clapham's group showed that IKAch, Adodeficient GIRK4 knockout mice exhibited a significantly faster sinus rate than wild-type mice 280 ; . They also reported that the bradycardic response to purinergic and cholinergic agonists and HRV are decreased in mice without functional IKAch, Ado channels 281 ; . As in patients with IST, the effect of adenosine on AV nodal conduction was influenced less than the effect on sinus rate 281. If, as sometimes happens in a small number of patients, a slight milk secretion is observed a couple of days after treatment is discontinued, treatment should be resumed or prolonged for a further week at one tablet daily, because irbesartan hctz.
Unbeatable prices and quality health information and news alzheimer's disease and dementia anxiety, panic disorder, depression antioxidants and vitamin deficiency arthritis, rheumatoid arthritis bacterial infections benign prostatic hyperplasia cancer cataract and glaucoma diabetes mellitus, type 2 fungal infections general premature aging heart attack hypertension hyperlipidemia iodine deficiency low immunity menopause and premenstrual disturbances migraine headaches memory loss muscle weakness osteoporosis parkinsonism seizure sexual disorders schizophrenia, psychosis stroke risk weight gaining weight loss other drugs avapro - aprovel - generic generic name: irbesartan reviews bibliography drug information order now j hypertens. Irbesartan was approved by suppressing drug. Short irbesartan guide: irbesartan -get online irbesartan - free meds rx online-free meds rx online-common description side effects free rx prescription: treat high blood pressure. Although it is laudable to see a trial that will roll out to substantial numbers of African people, we are simultaneously seeing disappointing results with similar stop and start strategies reported from the "Staccato" and National Institutes of AIDS and Infectious Diseases NIAID ; studies reported on pages 17-18. There are many outstanding questions for such strategies, notably resistance, complexities of adherence and, in this population particularly, stopping and starting therapy in people with very low baseline CD4 at initiation. Patients were randomly assigned centrally by computer to receive treatment with irbesartan, 300 mg d Avapro, Bristol-Myers Squibb, Princeton, New Jersey amlodipine, 10 mg d Norvasc, Pfizer, New York or matched placebo. To minimize any center effect, randomization was blocked by center. All patients had blood pressure controlled to the same blood pressure goal of less than 135 85 mm Hg using antihypertensive agents other than ACE inhibitors, angiotensin II receptor blocking agents, or calcium-channel blockers. For the analysis of cardiovascular end points, patients were followed to initiation of treatment for end-stage renal failure dialysis or renal transplantation ; , reaching a serum creatinine level of 530.4 mol L 6.0 mg dL ; or higher, death, or administrative censoring in December 2000.
Sanofi-Aventis Bristol-Myers Squibb Novartis AstraZeneca Daiichi Sankyo Servier GlaxoSmithKline Boehringer Ingelheim Chapter 6. Key trends and opportunities Key disease market forecasts Global markets Cardiovascular sites Key drug class forecasts Anti-hypertensives Anti-dyslipidemics Anti-thrombotics Selected others Key product forecasts Lipitor atorvastatin ; Plavix clopidogel ; Norvasc Amlodin amlodopine ; Zocor simvastatin ; Diovan Co-Diovan valsartan ; Pravachol Mevalotin pravastatin ; Cozaar Hyzaar losartan ; Lovenox enoxaparin ; Blopress Atacand candesartan ; Aprovel Avapro Avalide irbesartan ; Forecast patent expiries Key company forecasts Pfizer Merck Sanofi-Aventis Bristol-Myers Squibb Novartis AstraZeneca Daiichi Sankyo Servier GlaxoSmithKline Boehringer Ingelheim Appendix Proprietary data sources Product Trends Database R&D Trends Database Company Trends Database Market Trends Database Top 58 cardiovascular products Top 14 pharmaceutical companies by cardiovascular sales.